Inventiva (IVA) Interest Expenses (2019 - 2025)
Inventiva's (IVA) quarterly Interest Expenses came in at -$130.7 million in Q2 2025, down 485455.24% year-on-year from N/an in Q2 2024, and down 489223.09% quarter-over-quarter from -$26714.9 in Q4 2024.
Inventiva (IVA) Interest Expenses (2019 - 2025) Analysis & Trends
Inventiva's Interest Expenses history runs 7 years deep, the most recent figure standing at -$130.7 million for Q2 2025.
- On a quarterly basis, Interest Expenses fell 485455.24% year-over-year to -$130.7 million in Q2 2025; TTM through Dec 2025 was -$130.7 million, a 489223.09% decrease from a year earlier, with the FY2025 full-year figure at $252.5 million, up 165.75% from the prior year.
- Interest Expenses retreated to -$130.7 million in Q2 2025 per IVA's latest filing, from -$26714.9 in the prior quarter.
- Across five years, Interest Expenses topped out at -$14283.5 in Q4 2022 and bottomed at -$130.7 million in Q2 2025.
- The 5-year median for Interest Expenses is -$38207.7 (2023), against an average of -$17.0 million.
- Across the five-year window, Interest Expenses surged 46.02% in 2024 and plunged 485455.24% in 2025, its largest moves.
- Year by year, Interest Expenses stood at -$2.6 million in 2021, then soared by 99.46% to -$14283.5 in 2022, then tumbled by 246.51% to -$49493.2 in 2023, then surged by 46.02% to -$26714.9 in 2024, then tumbled by 489223.09% to -$130.7 million in 2025.
- Per Business Quant, the three latest IVA Interest Expenses figures stand at -$130.7 million (Q2 2025), -$26714.9 (Q4 2024), and -$26922.2 (Q2 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 32.89 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 16.81 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.17 Bn |
| 10 | Inventiva | 842.48 Mn | 842.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -130.72 Mn |
| Jun 30, 2025 | -130.72 Mn |
| Dec 31, 2024 | -26,714.89 |
| Dec 31, 2024 | -26,714.89 |
| Jun 30, 2024 | -26,922.19 |
| Jun 30, 2024 | -26,922.19 |
| Dec 31, 2023 | -49,493.24 |
| Dec 31, 2023 | -49,493.24 |
| Jun 30, 2023 | -25,045.26 |
| Jun 30, 2023 | -25,045.26 |
| Dec 31, 2022 | -14,283.46 |
| Dec 31, 2022 | -14,283.46 |
| Jun 30, 2021 | -2.64 Mn |
| Jun 30, 2021 | -2.64 Mn |
| Mar 31, 2021 | -2.71 Mn |
| Mar 31, 2021 | -2.71 Mn |
| Jun 30, 2020 | -30,840.88 |
| Jun 30, 2020 | -30,840.88 |
| Mar 31, 2020 | -14,351.21 |
| Mar 31, 2020 | -14,351.21 |